Alkermes Dividends and Buybacks
Dividend criteria checks 0/6
Alkermes does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.2%
Buyback Yield
| Total Shareholder Yield | -0.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 31
Alkermes: A More Than Solid Quarter
Jul 30Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation?
May 31Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors
Apr 21Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Feb 25Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price
Jan 16We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt
Dec 17Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Nov 24Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement
Oct 14Is Alkermes (NASDAQ:ALKS) A Risky Investment?
Sep 17
Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges
Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.Alkermes: Fairly Valued After Post-Earnings Bump
Jul 28Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?
Jul 26Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry
Jul 04The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals
May 08Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Jan 26Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Nov 01Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point
Nov 01Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
Jul 15There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding
Jun 07Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?
Apr 10Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Mar 20Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ALKS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALKS's dividend payments have been increasing.
Dividend Yield vs Market
| Alkermes Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ALKS) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (ALKS) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ALKS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALKS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ALKS's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALKS has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 14:16 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkermes plc is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |